drugset / Trial / NCT06514066

Cannabidiol's Role in Dementia Management

NCT06514066

RandomizedCrossoverDouble-blindSupportive care

Summary

This trial investigates the therapeutic benefits of cannabidiol (CBD) for Dementia patients in Malaysia. As dementia becomes increasingly prevalent worldwide, there's a pressing demand for impactful remedies. This research will delve into CBD's influence on cognitive functions, daily activities, mental health, and overall life quality of dementia sufferers. Utilizing a range of established assessment instruments, including the ADAS-COG subscale for cognitive effects, the NPI score for psychological well-being, and the QOLAD questionnaire for life quality, we aim to discern CBD's potential in ameliorating the conditions of those with dementia. This study's results could shape novel treatment methods and improved care for dementia patients, benefiting not just Malaysia but the world at large.

Timeline

Start
2024-09-01
Primary completion
2025-10-01
Completion
2025-10-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Cannabidiol Other / unclassified 400 mg

Indications